Compare GILT & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GILT | ABSI |
|---|---|---|
| Founded | 1987 | 2011 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 843.0M | 997.8M |
| IPO Year | 1997 | 2021 |
| Metric | GILT | ABSI |
|---|---|---|
| Price | $11.64 | $8.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $19.00 | $6.96 |
| AVG Volume (30 Days) | 692.7K | ★ 7.7M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,534,000.00 |
| Revenue This Year | $15.06 | $215.96 |
| Revenue Next Year | $11.72 | $319.10 |
| P/E Ratio | $42.82 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.22 | $2.24 |
| 52 Week High | $20.99 | $12.06 |
| Indicator | GILT | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 41.32 | 42.90 |
| Support Level | $11.40 | $2.80 |
| Resistance Level | $13.82 | $12.06 |
| Average True Range (ATR) | 0.60 | 0.79 |
| MACD | 0.03 | -0.51 |
| Stochastic Oscillator | 31.57 | 15.38 |
Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company operates in three operating segments: Gilat Commercial Division, Gilat Defense Division, and Gilat Peru Division. The majority of its revenue is generated from the Gilat Commercial segment.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.